| CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies (NCT07763938) | The First Affiliated Hospital with Nanjing Medical University | 2026-11-01 |
| A Study of the LVIVO-TaVec122 Product in Subjects With Relapsed/Refractory B-cell Malignancies (NCT07628582) | The First Affiliated Hospital with Nanjing Medical University | 2026-09-15 |
| Adjuvant Therapy for Potentially Immunotherapy-Responsive Gastric or Gastroesophageal Junction Adenocarcinoma (NCT07772557) | The First Affiliated Hospital with Nanjing Medical University | 2026-09-01 |
| Neoadjuvant Short-course Hypofractionated Radiotherapy Plus Adebrelimab and Platinum Chemotherapy in Locally Advanced Cervical Cancer: A Single-arm Phase II Trial (NCT07731828) | The First Affiliated Hospital with Nanjing Medical University | 2026-08-01 |
| The Efficacy of CAPCT in Patients With PTCL (NCT07746245) | The First Affiliated Hospital with Nanjing Medical University | 2026-08-01 |
| A Prospective Cohort Study on the Epidemiological Investigation, Diagnosis, and Treatment of Hepatic Encephalopathy (NCT07612670) | The First Affiliated Hospital with Nanjing Medical University | 2026-08-01 |
| Safety and Efficacy of Esketamine - Dexmedetomidine Combination Versus Dexmedetomidine Monotherapy for Hyperactive Delirium in ICU Patients on Non-Invasive Respiratory Support (ESSENTIAL Trial): Study Protocol of a Randomized Controlled Trial (NCT07377981) | The First Affiliated Hospital with Nanjing Medical University | 2026-08-01 |
| Prospective Cohort Study of Local Recurrence After Radical Breast Cancer Resection (NCT07668362) | The First Affiliated Hospital with Nanjing Medical University | 2026-07-20 |
| Neoadjuvant SHR-A1811 and SHR-A1701 ± Pertuzumab for Potentially Immunotherapy-Sensitive GC or GEJ Adenocarcinoma (NCT07716111) | The First Affiliated Hospital with Nanjing Medical University | 2026-07-16 |
| Safety of Breast-Conserving Surgery for Multifocal or Multicentric Breast Cancer (NCT07677956) | The First Affiliated Hospital with Nanjing Medical University | 2026-07-15 |
| Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL) (NCT07719556) | The First Affiliated Hospital with Nanjing Medical University | 2026-07-15 |
| Ultrasound Screening for Early Detection of Breast Cancer in Elderly Women: A Mixed Cluster-Individual RCT (NCT07698366) | The First Affiliated Hospital with Nanjing Medical University | 2026-07-10 |
| A Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-term Recurrence After Adjuvant Therapy (NCT07669740) | The First Affiliated Hospital with Nanjing Medical University | 2026-07-01 |
| Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma (NCT07628595) | The First Affiliated Hospital with Nanjing Medical University | 2026-07-01 |
| Intra-arterial Thrombolysis For Acute Ischemic Stroke With Medium Vessel Occlusion (NCT07668323) | The First Affiliated Hospital with Nanjing Medical University | 2026-07-01 |
| The Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation for Depression in PD (NCT07679529) | The First Affiliated Hospital with Nanjing Medical University | 2026-07-01 |
| Study on the Thrombolytic Effect of Platelet Membrane Coated Tenecteplase on Human Arterial Thrombus (NCT07712445) | The First Affiliated Hospital with Nanjing Medical University | 2026-06-30 |
| A Biomarker Exploration Study for Predicting Localization of Recurrence and Metastasis in Colorectal Cancer (PROBE Study) (NCT07685236) | The First Affiliated Hospital with Nanjing Medical University | 2026-06-29 |
| Early Screening for Multiple Myeloma Based on Liquid Biopsy cfDNA Fragmentomics (NCT07684274) | The First Affiliated Hospital with Nanjing Medical University | 2026-06-13 |
| A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer. (NCT07622836) | The First Affiliated Hospital with Nanjing Medical University | 2026-06-05 |
| Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes (NCT07608978) | The First Affiliated Hospital with Nanjing Medical University | 2026-06-01 |
| A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients (NCT07671378) | The First Affiliated Hospital with Nanjing Medical University | 2026-06-01 |
| Single-Arm Clinical Study of EZH2i in Combination With Glofitamab + GemOx in Patients With Relapsed/ Refractory DLBCL (NCT07643805) | The First Affiliated Hospital with Nanjing Medical University | 2026-06-01 |
| Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP (NCT07589699) | The First Affiliated Hospital with Nanjing Medical University | 2026-05-31 |
| Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC (NCT07646639) | The First Affiliated Hospital with Nanjing Medical University | 2026-05-20 |
| Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases (NCT07558850) | The First Affiliated Hospital with Nanjing Medical University | 2026-05-10 |
| RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas (NCT07563543) | The First Affiliated Hospital with Nanjing Medical University | 2026-05-08 |
| Neoadjuvant SHR-A1811 and SHR-A1701 for Potentially Immunotherapy-Sensitive GC or GEJ Adenocarcinoma (NCT07581574) | The First Affiliated Hospital with Nanjing Medical University | 2026-05-01 |
| Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC (NCT07523789) | The First Affiliated Hospital with Nanjing Medical University | 2026-05-01 |
| SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer (NCT07464756) | The First Affiliated Hospital with Nanjing Medical University | 2026-04-03 |
| Full-Endoscopic Decompression vs. Endoscopic Lumbar Fusion for Middle-Aged and Older Adults With Spinal Stenosis (NCT07482826) | The First Affiliated Hospital with Nanjing Medical University | 2026-04-01 |
| Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes (NCT07558863) | The First Affiliated Hospital with Nanjing Medical University | 2026-04-01 |
| Dihydroartemisinin for MAFLD (NCT07679542) | The First Affiliated Hospital with Nanjing Medical University | 2026-03-30 |
| Safety and Efficacy of SC101 Via Perirenal Fat Injection for Resistant Hypertension in Patients With Moderate to Severe Chronic Kidney Disease (NCT07483372) | The First Affiliated Hospital with Nanjing Medical University | 2026-03-27 |
| Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial (NCT07474324) | The First Affiliated Hospital with Nanjing Medical University | 2026-03-15 |
| Comparison of Breast Sensory Recovery Between Conventional and Endoscopic Nipple-Sparing Mastectomy Combined With Prepectoral Implant Reconstruction (NCT07372339) | The First Affiliated Hospital with Nanjing Medical University | 2026-03-01 |
| First-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Dual Immunotherapy Combined With Chemotherapy (NCT07400315) | The First Affiliated Hospital with Nanjing Medical University | 2026-03-01 |
| A Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT) (NCT07471165) | The First Affiliated Hospital with Nanjing Medical University | 2026-03-01 |
| Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL (NCT07389356) | The First Affiliated Hospital with Nanjing Medical University | 2026-02-25 |
| Megestrol Acetate Oral Suspension for Cachexia in Patients With cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Receiving Neoadjuvant Therapy With Serplulimab Combined With SOX (NCT07391826) | The First Affiliated Hospital with Nanjing Medical University | 2026-02-15 |
| Intravascular Imaging-Guided Intravascular Lithotripsy for Severe Coronary Calcified Lesions. (NCT07444346) | The First Affiliated Hospital with Nanjing Medical University | 2026-02-10 |
| Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib (NCT07396454) | The First Affiliated Hospital with Nanjing Medical University | 2026-02-10 |
| Study in Human iPSCs-derived RPE Cells Transplantation for Late-Stage AMD (NCT07418177) | The First Affiliated Hospital with Nanjing Medical University | 2026-02-10 |
| PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL. (NCT07410520) | The First Affiliated Hospital with Nanjing Medical University | 2026-02-07 |
| Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma (NCT07418190) | The First Affiliated Hospital with Nanjing Medical University | 2026-02-01 |
| SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma (NCT07347288) | The First Affiliated Hospital with Nanjing Medical University | 2026-02-01 |
| Robotic vs Laparoscopic Gastrectomy for cT4a Gastric Cancer (NCT07331454) | The First Affiliated Hospital with Nanjing Medical University | 2026-02-01 |
| Safety of Robotic Surgery for GISTs at Special Anatomic Sites (NCT07405125) | The First Affiliated Hospital with Nanjing Medical University | 2026-02-01 |
| A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer (NCT07438106) | The First Affiliated Hospital with Nanjing Medical University | 2026-01-28 |
| 7-Day Vonoprazan, High-Dose Amoxicillin, and Bismuth Therapy (NCT07232095) | The First Affiliated Hospital with Nanjing Medical University | 2026-01-08 |
| QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer (NCT07315035) | The First Affiliated Hospital with Nanjing Medical University | 2026-01-01 |
| Remimazolam for Reducing Postoperative Delirium in Elderly Patients Undergoing Laparoscopic Gastrectomy (NCT07351474) | The First Affiliated Hospital with Nanjing Medical University | 2026-01-01 |
| To Evaluate the Effectiveness and Safety of Single-port Robotic-assisted Subcutaneous Gland Resection in Males (NCT07353411) | The First Affiliated Hospital with Nanjing Medical University | 2026-01-01 |
| Clinical Study of LV009 Injection in the Treatment of Recurrent/Refractory CD19 Positive Blood Tumors (NCT07330895) | The First Affiliated Hospital with Nanjing Medical University | 2025-12-31 |
| Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy (NCT07371247) | The First Affiliated Hospital with Nanjing Medical University | 2025-12-20 |
| Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma (NCT07277439) | The First Affiliated Hospital with Nanjing Medical University | 2025-12-16 |
| A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma (NCT07294625) | The First Affiliated Hospital with Nanjing Medical University | 2025-12-10 |
| Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer (NCT07277452) | The First Affiliated Hospital with Nanjing Medical University | 2025-12-10 |
| Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy (NCT06958705) | The First Affiliated Hospital with Nanjing Medical University | 2025-12-01 |
| Clinical Outcomes and Immunotherapy in Lung Cancer With Pulmonary Fibrosis (NCT07396467) | The First Affiliated Hospital with Nanjing Medical University | 2025-11-01 |
| Real-World Study of Crisugabalin(HSK16149) for the Treatment of Rosacea (NCT07606820) | The First Affiliated Hospital with Nanjing Medical University | 2025-10-29 |
| Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal Metastasis (NCT07263425) | The First Affiliated Hospital with Nanjing Medical University | 2025-10-27 |
| A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer (NCT07263386) | The First Affiliated Hospital with Nanjing Medical University | 2025-10-23 |
| An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies (NCT07668453) | The First Affiliated Hospital with Nanjing Medical University | 2025-10-20 |
| A Prospective, Single-arm, Multicenter Exploratory Clinical Study of Anlotinib Combined With Bempegaldesleukin and Conventional Chemoradiotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma. (NCT07156643) | The First Affiliated Hospital with Nanjing Medical University | 2025-10-01 |
| An Exploratory Clinical Study on the Safety and Efficacy of Autologous NK Cells in the Treatment of Pulmonary Nodules (NCT07185035) | The First Affiliated Hospital with Nanjing Medical University | 2025-09-20 |
| Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Gastric/Gastroesophageal Junction Adenocarcinoma (NCT07148427) | The First Affiliated Hospital with Nanjing Medical University | 2025-09-20 |
| Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS (NCT06925555) | The First Affiliated Hospital with Nanjing Medical University | 2025-09-01 |
| Feasibility and Safety of Laparoscopic Purse-string Suture Clamp and Multi-functional Seal Cap for Totally Laparoscopic Radical Total Gastrectomy (NCT07117812) | The First Affiliated Hospital with Nanjing Medical University | 2025-09-01 |
| Rapid Detection of Pseudomonas Aeruginosa in Bronchoalveolar Lavage Fluid Using Label-free Single-particle Imaging Technology and Assessment of Post-treatment Efficacy in Patients With Pseudomonas Aeruginosa Infection (NCT06986512) | The First Affiliated Hospital with Nanjing Medical University | 2025-09-01 |
| Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Potentially Resectable MSI-H, dMMR Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (NCT07151209) | The First Affiliated Hospital with Nanjing Medical University | 2025-09-01 |
| Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial (NCT07050524) | The First Affiliated Hospital with Nanjing Medical University | 2025-09-01 |
| Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer (NCT07718490) | The First Affiliated Hospital with Nanjing Medical University | 2025-09-01 |
| Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01) (NCT07134101) | The First Affiliated Hospital with Nanjing Medical University | 2025-09-01 |
| The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study (NCT07240194) | The First Affiliated Hospital with Nanjing Medical University | 2025-09-01 |
| Study on Proteomic and Microbiome Changes in Patients With Hepatic Encephalopathy (HE) (NCT07150195) | The First Affiliated Hospital with Nanjing Medical University | 2025-09-01 |
| Diagnostic Application of AI-ROSE in Severe Pneumonia (NCT07113951) | The First Affiliated Hospital with Nanjing Medical University | 2025-08-31 |
| QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD) (NCT07113964) | The First Affiliated Hospital with Nanjing Medical University | 2025-08-30 |
| Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL (NCT07208981) | The First Affiliated Hospital with Nanjing Medical University | 2025-08-14 |
| A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma (NCT07131501) | The First Affiliated Hospital with Nanjing Medical University | 2025-08-11 |
| RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies (NCT07113496) | The First Affiliated Hospital with Nanjing Medical University | 2025-08-01 |
| AI-Assisted Detection and Staging of Gastric Cancer Using Contrast-Enhanced CT (NCT07250347) | The First Affiliated Hospital with Nanjing Medical University | 2025-08-01 |
| RN1201 Injection for Autoimmune Diseases Refractory to Standard Therapies (NCT07105735) | The First Affiliated Hospital with Nanjing Medical University | 2025-08-01 |
| Colorectal Cancer Screening in Chinese Rural Communities (NCT07180303) | The First Affiliated Hospital with Nanjing Medical University | 2025-08-01 |
| A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC (NCT06977828) | The First Affiliated Hospital with Nanjing Medical University | 2025-07-20 |
| Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma (NCT07126678) | The First Affiliated Hospital with Nanjing Medical University | 2025-07-15 |
| Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRT (NCT07309211) | The First Affiliated Hospital with Nanjing Medical University | 2025-07-08 |
| Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence/Metastasis (NCT06779318) | The First Affiliated Hospital with Nanjing Medical University | 2025-07-01 |
| A Trial on the Treatment of Bronchial Asthma With Budesonide Formoterol Combined With Immune Modulators (Staphylococcus and Neisseria Tablets) (NCT06895460) | The First Affiliated Hospital with Nanjing Medical University | 2025-06-20 |
| The Risk Factors Related to Rupture Flow-related Aneurysms in Posterior AVM (NCT07050381) | The First Affiliated Hospital with Nanjing Medical University | 2025-06-13 |
| The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies (NCT07002112) | The First Affiliated Hospital with Nanjing Medical University | 2025-05-23 |
| An Exploratory Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Antisynthetase Antibody Syndrome and Rheumatoid Arthritis (NCT06613490) | The First Affiliated Hospital with Nanjing Medical University | 2025-05-20 |
| A Study of GD007 (Human iPSC-Exosome Liquid Dressing) for Safety and Dose-Finding in Moderate-Severe Intrauterine Adhesions (NCT07101484) | The First Affiliated Hospital with Nanjing Medical University | 2025-05-04 |
| A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer (NCT07455019) | The First Affiliated Hospital with Nanjing Medical University | 2025-05-01 |
| A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL. (NCT06953739) | The First Affiliated Hospital with Nanjing Medical University | 2025-05-01 |
| VA Dual Sequential Therapy (NCT06929962) | The First Affiliated Hospital with Nanjing Medical University | 2025-04-24 |
| Circumferential Pulmonary Vein Isolation Plus Transition Zone Modification in Atrial Fibrillation Patients Without Low-Voltage Areas (NCT06930599) | The First Affiliated Hospital with Nanjing Medical University | 2025-04-09 |
| Effect of ADT and ARPI on Bone Loss of Patients with Prostate Cancer (NCT06838520) | The First Affiliated Hospital with Nanjing Medical University | 2025-04-01 |
| Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL (NCT07448324) | The First Affiliated Hospital with Nanjing Medical University | 2025-04-01 |
| Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma (NCT06838910) | The First Affiliated Hospital with Nanjing Medical University | 2025-03-31 |